Factor V and Thrombotic Disease: Description of a Janus-Faced Protein

@article{Nicolaes2002FactorVA,
  title={Factor V and Thrombotic Disease: Description of a Janus-Faced Protein},
  author={Gerry A. F. Nicolaes and Bj{\"o}rn Dahlb{\"a}ck},
  journal={Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association},
  year={2002},
  volume={22},
  pages={530-538}
}
  • G. Nicolaes, B. Dahlbäck
  • Published 1 April 2002
  • Biology, Medicine
  • Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association
The generation of thrombin by the prothrombinase complex constitutes an essential step in hemostasis, with thrombin being crucial for the amplification of blood coagulation, fibrin formation, and platelet activation. In the prothrombinase complex, the activated form of coagulation factor V (FVa) is an essential cofactor to the enzyme-activated factor X (FXa), FXa being virtually ineffective in the absence of its cofactor. Besides its procoagulant potential, intact factor V (FV) has an… Expand
Factor V Leiden: a disorder of factor V anticoagulant function
TLDR
The APC-cofactor activity of FV and its impairment in FV Leiden can explain the different thrombosis risks associated with heterozygosity, homozygosity and pseudo-homozygosity for FVLeiden. Expand
Inherited defects of coagulation factor V: the hemorrhagic side
TLDR
This review will focus on bleeding disorders associated with altered levels of type I FV deficiency, which is characterized by a remarkable genetic heterogeneity and by an uneven distribution of mutations throughout the FV gene. Expand
Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System: Lessons From a Tick Salivary Protein
TLDR
The data elucidate a unique molecular mechanism by which ticks inhibit the host’s coagulation system and propose a revised blood coagulated scheme in which direct FXa-mediated FV activation occurs in the initiation phase during which thrombin-mediated fibrinogen and inhibitors are restrained. Expand
Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S
  • B. Dahlbäck
  • Chemistry, Medicine
  • Journal of thrombosis and haemostasis : JTH
  • 2017
TLDR
The novel insights gained into the interaction between FV isoforms, TFPIα, and protein S have opened a new avenue for research about the mechanisms of coagulation regulation and also for future development of therapeutics aimed at modulating coagulations. Expand
Coagulation factor V.
TLDR
Given the dual role of FV, genetic defects in FV gene may result in opposite hemorrhagic or thrombotic phenotypes as well as on the genetic defects associated with mutations in the FV genes. Expand
Factor V Leiden in blood donors in Baghdad (Iraq).
TLDR
Resistance to APC action leads to increased risk of thrombosis and is mostly attributable to a single point mutation in the factor V gene (factor V Leiden) with a G-to-A substitution at nucleotide 1691. Expand
Progress in the understanding of the protein C anticoagulant pathway
  • B. Dahlbäck
  • Biology, Medicine
  • International journal of hematology
  • 2004
TLDR
APC has emerged in recent years as a useful therapeutic compound in the treatment of severe septic shock and is believed be due to both its anticoagulant and its anti-inflammatory properties. Expand
ACTIVATION OF FACTOR V BY VENOM PROTEASES
TLDR
An up-to-date overview of venom proteases that possess the capacity to activate or inactivate coagulation factor V and a novel detailed three-dimensional homology model for RVV-V, the factor V activator from Russell's viper venom is presented. Expand
Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure–Function Relationships and Molecular Recognition
The protein C system provides important control of blood coagulation by regulating the activities of factor VIIIa (FVIIIa) and factor Va (FVa), cofactors in the activation of factor X andExpand
Factor V Leiden
TLDR
The FV Leiden mutation is the result of a single mutation event that is estimated to have occurred around 20–25 000 years ago in a Caucasian ancestor, which explains why the mutation is highly prevalent in Caucasian and rare in other ethnic groups. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 126 REFERENCES
Thrombophilia: the discovery of activated protein C resistance.
TLDR
This chapter focuses on a physiologically important natural anticoagulant system which is known as protein C system, which regulates blood coagulation by cleaving and inhibiting the activated forms of coagulations cofactors V and VIII (Va and VIIIa). Expand
Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
TLDR
An intricate mechanism of regulation of thrombin formation via the protein C pathway is starting to emerge and extensive studies in plasma milieu will be needed to gain more insight into the relation between the presence of FV Leiden and impaired downregulation of thROMbin formation in APC-resistant individuals. Expand
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
  • B. Dahlbäck
  • Biology, Medicine
  • Seminars in thrombosis and hemostasis
  • 1999
TLDR
In patients with severe thrombophilia having other inherited defects such as deficiencies of protein S, protein C, or antithrombin, APC resistance is often found as a contributing genetic risk factor. Expand
Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.
TLDR
It is shown that increased expression of FV anticoagulant activity correlates with APC-mediated cleavage at Arg-506 in FV, but not with cleavageAt Arg-306 nor atArg-679. Expand
The C-terminal Region of the Factor V B-domain Is Crucial for the Anticoagulant Activity of Factor V*
TLDR
To elucidate which effect the different thrombin cleavages in FV have on the ability of FV to express APC-cofactor activity, seven recombinant FV mutants containing all possible combinations of mutated and native throm bin cleavage sites were tested in a FVIIIa degradation assay. Expand
Mutation in blood coagulation factor V associated with resistance to activated protein C
TLDR
It is demonstrated that the phenotype of APC resistance is associated with hetero-zygosity or homozygosity for a single point mutation in the factor V gene which predicts the synthesis of a factor V molecule that is not properly inactivated by APC. Expand
The contribution of bovine Factor V and Factor Va to the activity of prothrombinase.
TLDR
The present data indicate that the model prothrombinase described in this paper consists of a phospholipid-bound, stoichiometric complex of Factor Va and Factor Xa, with bound Factor Va serving as the "binding site" for Factor V, in concert with its proposed role in platelets. Expand
Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.
TLDR
The results suggest that factor V and protein S work in synergy as phospholipid-bound cofactors to APC. Expand
Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways.
TLDR
In the process of generation, expression, and down-regulation of factor Va cofactor activity on physiological membranes, the overall procoagulant activity of factor V1 can considerably exceed that offactor V2. Expand
The role of phospholipids and factor Va in the prothrombinase complex.
TLDR
Both in the absence and presence of phospholipid but without factor Va, prethrombin 2 is the main product formed during the initial stages of steady state prothrom bin activation, and the Vmax of thrombin formation slightly increases when more phospholipsid is present in the authors' experiments and there is a considerable increase of the Km for prothROMbin at higher phospholIPid concentrations. Expand
...
1
2
3
4
5
...